BMI vs NVDA

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating marginal financial health, and the absence of an Altman Z-Score prevents a full solvency risk assessment. Despite solid profitability metrics like 21.45% ROE and 19.57% operating margin, elevated valuation (P/E of 36.77 vs. sector average of 84.87) and bearish technical trend (0/100) offset strength in fundamentals. Revenue and earnings growth remain positive at 13.1% and 10.2% YoY, but recent price performance is sharply negative (-22% over 1Y), and analyst target suggests upside to $211.30. The stock trades well above the Graham Number of $49.73, reflecting premium pricing for growth expectations despite mixed earnings surprise trends.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.